Verrica Doses First Patient in Phase 3 Wart Trial, Eyes Major Label Expansion

Verrica Doses First Patient in Phase 3 Wart Trial, Eyes Major Label Expansion

WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) said it has dosed the first patient in its global Phase 3 clinical program evaluating YCANTH (VP-102) for the treatment of common warts, marking a significant step in the company’s strategy to expand the drug’s label and commercial reach. The first patient was dosed in December 2025, launching a late-stage program aimed at a condition that affects an estimated 22 million people in th…

First Patient Dosed in Phase 3 VP-102 Common Warts Program

Verrica Pharmaceuticals initiates phase 3 trials for VP-102, aiming to provide an effective treatment for common warts, addressing significant unmet needs.